| Date Filed | Type | Description |
| 08/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in Kinnate Biopharma Inc. |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 07/28/2023 |
8-K
| Quarterly results |
| 06/12/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
SC 13D/A
| Foresite Capital Fund IV, L.P. reports a 29.5% stake in Kinnate Biopharma Inc. |
| 05/08/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 16.2% stake in Kinnate Biopharma Inc. |
| 05/02/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 13.1% stake in Kinnate Biopharma Inc. |
| 04/17/2023 |
8-K
| Quarterly results |
| 04/06/2023 |
SC 13G/A
| BlackRock Inc. reports a 4.9% stake in Kinnate Biopharma Inc |
| 03/17/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/15/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/15/2023 |
8-K
| Quarterly results |
| 02/23/2023 |
SC 13D/A
| ORBIMED ADVISORS LLC reports a 10.6% stake in Kinnate Biopharma Inc. |
| 02/22/2023 |
SC 13D/A
| Foresite Capital Fund IV, L.P. reports a 25.6% stake in Kinnate Biopharma Inc. |
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 9.7% stake in Kinnate Biopharma Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/26/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/23/2023 |
SC 13G
| Lynx1 Capital Management LP reports a 5% stake in Kinnate Biopharma Inc. |
| 10/11/2022 |
8-K
| Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits Interactive Data |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/11/2022 |
8-K
| Quarterly results |
| 06/15/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
10-K/A
| Annual Report for the period ended December 31, 2021 [amend] |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/12/2022 |
8-K
| Quarterly results |
| 04/27/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/25/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/28/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/28/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
|